<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT00101400">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00101400">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT00101400 on 2005_06_30</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Administrative, Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><span class="nolink" title="There is no version prior to this one."><img src="/archive/prev-g.gif" alt="" width="23" height="19" /></span></div><h2>Before</h2><h3><a href="/archive/NCT00101400/2005_06_23">(Updated 2005_06_23)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00101400/2005_12_08/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00101400/2005_06_30">(Updated 2005_06_30)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 10 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  Bayer</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Bayer Corporation</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  100555</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
</div><div class="sdl2 sds">&lt;nct_id&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 10 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  Bayer</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Bayer Corporation</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  100555</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
</div><div class="sdl2 sds">&lt;nct_id&gt;</div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"></div>
</td>
<td class="sdiff-b"><div class="sdl3">  NCT00101400</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-f13A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f13&#39;)" style="display:none" /><img id="sdiff-collapse-f13A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f13&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div id="sdiff-collapse-f13A-cdiv" class="sdiff-collapsed" title="The middle 183 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f13&#39;)" style="display:none"></div><div id="sdiff-collapse-f13A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Evaluate the Best Overall Response Rate of BAY 43-9006 in Subjects with Metastatic Breast Cancer</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Subjects with Metastatic Breast Cancer</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Bayer Corporation</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this multinational, multi-center, open label, uncontrolled, single arm phase II study is to assess the anti-tumor activity and safety profile of BAY 43-9006 as a single agent in subjects with metastatic breast cancer (MBC).  Subjects will be treated with BAY 43-9006 400 mg twice daily (b.i.d.) until there is objective evidence of tumor progression, evidence of toxicity that is unacceptable and thought to be related to study drug.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  No longer recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2005-01</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 2</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Uncontrolled</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2">  To evaluate the best overall response rate, including complete response and partial response, of BAY 43-9006</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze time to disease progression</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze time to response</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Anlayze duration of response</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze survival time</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Evaluate rate of non-responders</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Evaluate quantitative and qualitative toxicity</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Breast Cancer</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Metastases</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  BAY 43-9006, A Raf Kinase Inhibitor</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">    - Age &amp;gt; 18 years</div>
<div class="sdl4">    - Women with prior histologically documented diagnosis of breast cancer</div>
<div class="sdl4">    - Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and,</div>
<div class="sdl4">  if estrogen receptor/progesterone receptor positive (ER/PgR +ve), have failed on at least adjuvant hormonal therapy</div>
<div class="sdl4">    - Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects</div>
<div class="sdl4">    - Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy</div>
<div class="sdl4">    - Subjects who have at least one measurable lesion by CT scan or MRI</div>
<div class="sdl4">    - Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2</div>
<div class="sdl4">    - Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days</div>
<div class="sdl4">  prior to screening: *Hemoglobin &amp;gt; 9.0 g/dl, *Absolute neutrophil count (ANC) &amp;gt; 1,500/mm, *Platelet count &amp;#8805;100,000/&amp;#181;l, *Total bilirubin &amp;#8804;1.5 x the upper limit of normal, *ALT and AST &amp;#8804;2.5 x upper limit of normal (&amp;#8804;5 x upper limit of</div>
<div class="sdl4">  normal for subjects with liver involvement of their cancer).</div>
<div class="sdl4">    - Amylase and lipase &amp;#8804;1.5 x the upper limit of normal.</div>
<div class="sdl4">    - Serum creatinine &amp;#8804;3.0 x the upper limit of normal.</div>
<div class="sdl4">    - PT or INR and PTT &amp;lt; 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists).</div>
<div class="sdl4">    - Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice.</div>
<div class="sdl4">    - Life expectancy of at least 12 weeks</div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">    - Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1] or other malignancies curatively treated &amp;gt; 2 years prior to entry)</div>
<div class="sdl4">    - Congestive heart failure &amp;gt; NYHA Class II</div>
<div class="sdl4">    - Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin)</div>
<div class="sdl4">    - Active coronary artery disease or ischemia</div>
<div class="sdl4">    - Active clinically serious bacterial or fungal infections (&amp;gt; grade 2 NCI-CTC, Version 3)</div>
<div class="sdl4">    - Known History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C</div>
<div class="sdl4">    - Metastatic brain or meningeal tumors unless the subject is &amp;gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study).</div>
<div class="sdl4">    - Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics)</div>
<div class="sdl4">    - History of organ allograft</div>
<div class="sdl4">    - Substance abuse, medical, psychological or social conditions that may interfere with the subject&amp;#8217;s participation in the study or evaluation of the study results</div>
<div class="sdl4">    - Known or suspected allergy to the investigational agent</div>
<div class="sdl4">    - Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study</div>
<div class="sdl4">    - Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this</div>
<div class="sdl4">  trial must use adequate barrier birth control measures during the course of the trial</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Female</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  N/A</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Clinical Communications</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  800-288-8371</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
</div><div class="sdl1 sdz">&lt;/contact&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f13B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f13&#39;)" style="display:none" /><img id="sdiff-collapse-f13B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f13&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div id="sdiff-collapse-f13B-cdiv" class="sdiff-collapsed" title="The middle 183 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f13&#39;)" style="display:none"></div><div id="sdiff-collapse-f13B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Evaluate the Best Overall Response Rate of BAY 43-9006 in Subjects with Metastatic Breast Cancer</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Subjects with Metastatic Breast Cancer</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Bayer Corporation</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this multinational, multi-center, open label, uncontrolled, single arm phase II study is to assess the anti-tumor activity and safety profile of BAY 43-9006 as a single agent in subjects with metastatic breast cancer (MBC).  Subjects will be treated with BAY 43-9006 400 mg twice daily (b.i.d.) until there is objective evidence of tumor progression, evidence of toxicity that is unacceptable and thought to be related to study drug.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  No longer recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2005-01</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 2</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Uncontrolled</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2">  To evaluate the best overall response rate, including complete response and partial response, of BAY 43-9006</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze time to disease progression</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze time to response</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Anlayze duration of response</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze survival time</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Evaluate rate of non-responders</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Evaluate quantitative and qualitative toxicity</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Breast Cancer</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Metastases</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  BAY 43-9006, A Raf Kinase Inhibitor</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">    - Age &amp;gt; 18 years</div>
<div class="sdl4">    - Women with prior histologically documented diagnosis of breast cancer</div>
<div class="sdl4">    - Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and,</div>
<div class="sdl4">  if estrogen receptor/progesterone receptor positive (ER/PgR +ve), have failed on at least adjuvant hormonal therapy</div>
<div class="sdl4">    - Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects</div>
<div class="sdl4">    - Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy</div>
<div class="sdl4">    - Subjects who have at least one measurable lesion by CT scan or MRI</div>
<div class="sdl4">    - Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2</div>
<div class="sdl4">    - Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days</div>
<div class="sdl4">  prior to screening: *Hemoglobin &amp;gt; 9.0 g/dl, *Absolute neutrophil count (ANC) &amp;gt; 1,500/mm, *Platelet count &amp;#8805;100,000/&amp;#181;l, *Total bilirubin &amp;#8804;1.5 x the upper limit of normal, *ALT and AST &amp;#8804;2.5 x upper limit of normal (&amp;#8804;5 x upper limit of</div>
<div class="sdl4">  normal for subjects with liver involvement of their cancer).</div>
<div class="sdl4">    - Amylase and lipase &amp;#8804;1.5 x the upper limit of normal.</div>
<div class="sdl4">    - Serum creatinine &amp;#8804;3.0 x the upper limit of normal.</div>
<div class="sdl4">    - PT or INR and PTT &amp;lt; 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists).</div>
<div class="sdl4">    - Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice.</div>
<div class="sdl4">    - Life expectancy of at least 12 weeks</div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">    - Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1] or other malignancies curatively treated &amp;gt; 2 years prior to entry)</div>
<div class="sdl4">    - Congestive heart failure &amp;gt; NYHA Class II</div>
<div class="sdl4">    - Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin)</div>
<div class="sdl4">    - Active coronary artery disease or ischemia</div>
<div class="sdl4">    - Active clinically serious bacterial or fungal infections (&amp;gt; grade 2 NCI-CTC, Version 3)</div>
<div class="sdl4">    - Known History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C</div>
<div class="sdl4">    - Metastatic brain or meningeal tumors unless the subject is &amp;gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study).</div>
<div class="sdl4">    - Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics)</div>
<div class="sdl4">    - History of organ allograft</div>
<div class="sdl4">    - Substance abuse, medical, psychological or social conditions that may interfere with the subject&amp;#8217;s participation in the study or evaluation of the study results</div>
<div class="sdl4">    - Known or suspected allergy to the investigational agent</div>
<div class="sdl4">    - Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study</div>
<div class="sdl4">    - Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this</div>
<div class="sdl4">  trial must use adequate barrier birth control measures during the course of the trial</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Female</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  N/A</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Clinical Communications</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;phone&gt;</div>
<div class="sdl3">  800-288-8371</div>
<div class="sdl2 sdz">&lt;/phone&gt;</div>
<div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
</div><div class="sdl1 sdz">&lt;/contact&gt;</div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
</td>
<td class="sdiff-b"><div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2005-01-10</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2005-06-23</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><span class="nolink" title="There is no version prior to this one."><img src="/archive/prev-g.gif" alt="" width="23" height="19" /></span></div><h2>Before</h2><h3><a href="/archive/NCT00101400/2005_06_23">(Updated 2005_06_23)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00101400/2005_12_08/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00101400/2005_06_30">(Updated 2005_06_30)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 10 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  Bayer</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Bayer Corporation</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  100555</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
</div><div class="sdl2 sds">&lt;nct_id&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 10 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  Bayer</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Bayer Corporation</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  100555</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
</div><div class="sdl2 sds">&lt;nct_id&gt;</div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"></div>
</td>
<td class="sdiff-b"><div class="sdl3">  NCT00101400</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-m13A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m13&#39;)" style="display:none" /><img id="sdiff-collapse-m13A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m13&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div id="sdiff-collapse-m13A-cdiv" class="sdiff-collapsed" title="The middle 171 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m13&#39;)" style="display:none"></div><div id="sdiff-collapse-m13A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Evaluate the Best Overall Response Rate of BAY 43-9006 in Subjects with Metastatic Breast Cancer</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Subjects with Metastatic Breast Cancer</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Bayer Corporation</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this multinational, multi-center, open label, uncontrolled, single arm phase II study is to assess the anti-tumor activity and safety profile of BAY 43-9006 as a single agent in subjects with metastatic breast cancer (MBC).  Subjects will be treated with BAY 43-9006 400 mg twice daily (b.i.d.) until there is objective evidence of tumor progression, evidence of toxicity that is unacceptable and thought to be related to study drug.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  No longer recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2005-01</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 2</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Uncontrolled</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2">  To evaluate the best overall response rate, including complete response and partial response, of BAY 43-9006</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze time to disease progression</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze time to response</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Anlayze duration of response</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze survival time</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Evaluate rate of non-responders</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Evaluate quantitative and qualitative toxicity</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Breast Cancer</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Metastases</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  BAY 43-9006, A Raf Kinase Inhibitor</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">    - Age &amp;gt; 18 years</div>
<div class="sdl4">    - Women with prior histologically documented diagnosis of breast cancer</div>
<div class="sdl4">    - Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and,</div>
<div class="sdl4">  if estrogen receptor/progesterone receptor positive (ER/PgR +ve), have failed on at least adjuvant hormonal therapy</div>
<div class="sdl4">    - Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects</div>
<div class="sdl4">    - Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy</div>
<div class="sdl4">    - Subjects who have at least one measurable lesion by CT scan or MRI</div>
<div class="sdl4">    - Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2</div>
<div class="sdl4">    - Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days</div>
<div class="sdl4">  prior to screening: *Hemoglobin &amp;gt; 9.0 g/dl, *Absolute neutrophil count (ANC) &amp;gt; 1,500/mm, *Platelet count &amp;#8805;100,000/&amp;#181;l, *Total bilirubin &amp;#8804;1.5 x the upper limit of normal, *ALT and AST &amp;#8804;2.5 x upper limit of normal (&amp;#8804;5 x upper limit of</div>
<div class="sdl4">  normal for subjects with liver involvement of their cancer).</div>
<div class="sdl4">    - Amylase and lipase &amp;#8804;1.5 x the upper limit of normal.</div>
<div class="sdl4">    - Serum creatinine &amp;#8804;3.0 x the upper limit of normal.</div>
<div class="sdl4">    - PT or INR and PTT &amp;lt; 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists).</div>
<div class="sdl4">    - Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice.</div>
<div class="sdl4">    - Life expectancy of at least 12 weeks</div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">    - Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1] or other malignancies curatively treated &amp;gt; 2 years prior to entry)</div>
<div class="sdl4">    - Congestive heart failure &amp;gt; NYHA Class II</div>
<div class="sdl4">    - Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin)</div>
<div class="sdl4">    - Active coronary artery disease or ischemia</div>
<div class="sdl4">    - Active clinically serious bacterial or fungal infections (&amp;gt; grade 2 NCI-CTC, Version 3)</div>
<div class="sdl4">    - Known History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C</div>
<div class="sdl4">    - Metastatic brain or meningeal tumors unless the subject is &amp;gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study).</div>
<div class="sdl4">    - Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics)</div>
<div class="sdl4">    - History of organ allograft</div>
<div class="sdl4">    - Substance abuse, medical, psychological or social conditions that may interfere with the subject&amp;#8217;s participation in the study or evaluation of the study results</div>
<div class="sdl4">    - Known or suspected allergy to the investigational agent</div>
<div class="sdl4">    - Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study</div>
<div class="sdl4">    - Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this</div>
<div class="sdl4">  trial must use adequate barrier birth control measures during the course of the trial</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Female</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  N/A</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
</div><div class="sdl1 sdz">&lt;/eligibility&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m13B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m13&#39;)" style="display:none" /><img id="sdiff-collapse-m13B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m13&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div id="sdiff-collapse-m13B-cdiv" class="sdiff-collapsed" title="The middle 171 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m13&#39;)" style="display:none"></div><div id="sdiff-collapse-m13B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Evaluate the Best Overall Response Rate of BAY 43-9006 in Subjects with Metastatic Breast Cancer</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Subjects with Metastatic Breast Cancer</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Bayer Corporation</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this multinational, multi-center, open label, uncontrolled, single arm phase II study is to assess the anti-tumor activity and safety profile of BAY 43-9006 as a single agent in subjects with metastatic breast cancer (MBC).  Subjects will be treated with BAY 43-9006 400 mg twice daily (b.i.d.) until there is objective evidence of tumor progression, evidence of toxicity that is unacceptable and thought to be related to study drug.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  No longer recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2005-01</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sds">&lt;end_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/end_date&gt;</div>
<div class="sdl1 sds">&lt;last_follow_up_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sds">&lt;last_data_entry_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_data_entry_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 2</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Uncontrolled</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2">  To evaluate the best overall response rate, including complete response and partial response, of BAY 43-9006</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze time to disease progression</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze time to response</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Anlayze duration of response</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Analyze survival time</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Evaluate rate of non-responders</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2">  Evaluate quantitative and qualitative toxicity</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Breast Cancer</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Metastases</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  BAY 43-9006, A Raf Kinase Inhibitor</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">    - Age &amp;gt; 18 years</div>
<div class="sdl4">    - Women with prior histologically documented diagnosis of breast cancer</div>
<div class="sdl4">    - Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and,</div>
<div class="sdl4">  if estrogen receptor/progesterone receptor positive (ER/PgR +ve), have failed on at least adjuvant hormonal therapy</div>
<div class="sdl4">    - Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects</div>
<div class="sdl4">    - Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy</div>
<div class="sdl4">    - Subjects who have at least one measurable lesion by CT scan or MRI</div>
<div class="sdl4">    - Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2</div>
<div class="sdl4">    - Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days</div>
<div class="sdl4">  prior to screening: *Hemoglobin &amp;gt; 9.0 g/dl, *Absolute neutrophil count (ANC) &amp;gt; 1,500/mm, *Platelet count &amp;#8805;100,000/&amp;#181;l, *Total bilirubin &amp;#8804;1.5 x the upper limit of normal, *ALT and AST &amp;#8804;2.5 x upper limit of normal (&amp;#8804;5 x upper limit of</div>
<div class="sdl4">  normal for subjects with liver involvement of their cancer).</div>
<div class="sdl4">    - Amylase and lipase &amp;#8804;1.5 x the upper limit of normal.</div>
<div class="sdl4">    - Serum creatinine &amp;#8804;3.0 x the upper limit of normal.</div>
<div class="sdl4">    - PT or INR and PTT &amp;lt; 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists).</div>
<div class="sdl4">    - Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice.</div>
<div class="sdl4">    - Life expectancy of at least 12 weeks</div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">    - Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1] or other malignancies curatively treated &amp;gt; 2 years prior to entry)</div>
<div class="sdl4">    - Congestive heart failure &amp;gt; NYHA Class II</div>
<div class="sdl4">    - Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin)</div>
<div class="sdl4">    - Active coronary artery disease or ischemia</div>
<div class="sdl4">    - Active clinically serious bacterial or fungal infections (&amp;gt; grade 2 NCI-CTC, Version 3)</div>
<div class="sdl4">    - Known History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C</div>
<div class="sdl4">    - Metastatic brain or meningeal tumors unless the subject is &amp;gt; 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study).</div>
<div class="sdl4">    - Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics)</div>
<div class="sdl4">    - History of organ allograft</div>
<div class="sdl4">    - Substance abuse, medical, psychological or social conditions that may interfere with the subject&amp;#8217;s participation in the study or evaluation of the study results</div>
<div class="sdl4">    - Known or suspected allergy to the investigational agent</div>
<div class="sdl4">    - Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study</div>
<div class="sdl4">    - Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this</div>
<div class="sdl4">  trial must use adequate barrier birth control measures during the course of the trial</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;patients&gt;</div>
<div class="sdl2 sdz">&lt;/patients&gt;</div>
<div class="sdl2 sds">&lt;expected_enrollment&gt;</div>
<div class="sdl2 sdz">&lt;/expected_enrollment&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Female</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  18 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  N/A</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
</div><div class="sdl1 sdz">&lt;/eligibility&gt;</div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
</td>
<td class="sdiff-b"><div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2005-01-10</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
<div class="sdl1 sds">&lt;last_release_date&gt;</div>
<div class="sdl2">  2005-06-23</div>
<div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f13');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m13');
SDiffInit();
</script></body></html>